Stories from Heidelberg, Germany

19.12.2024 – 11:43
RHEACELL GmbH und Co. KG
RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers
more
24.09.2024 – 12:25
RHEACELL GmbH und Co. KG
$RHEACELL GmbH und Co. KG: RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU$
RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU
more

1